What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The clinical effectiveness evidence for midostaurin is derived from two single-arm trials (D2201 and A2213), which do not provide direct comparisons with current treatment options. While the evidence suggests midostaurin may be more effective than existing treatments, the lack of direct comparative data and the uncertainty surrounding the results limit the strength of the evidence. The committee acknowledged that conducting a Phase 3 trial would be challenging due to the rarity of the condition, which further complicates the assessment of clinical effectiveness.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for midostaurin are below the NICE threshold of £50,000 per QALY gained, which is considered acceptable. The committee noted that midostaurin meets the criteria for a life-extending treatment at the end of life, allowing for higher cost-effectiveness estimates. Despite some uncertainties in the clinical evidence, the overall economic model was deemed broadly acceptable for decision making.
Is there quality-of-life evidence payers weigh? — Quality of life
Patient and clinical experts reported substantial improvements in quality of life following treatment with midostaurin, with some patients experiencing significant benefits shortly after starting treatment. However, the utility values used in the economic model were derived from the single-arm trials and did not include data from current clinical management, which may not fully capture the quality-of-life benefits. Despite this limitation, the evidence suggests a moderate improvement in HRQoL.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Midostaurin has a good safety profile, with adverse events primarily being mild to moderate. The committee noted that while there are some concerns regarding adverse effects, they are manageable and do not significantly undermine the overall benefit of the treatment. The evidence suggests that the safety profile is comparable to or better than existing therapies.
Was the drug compared against what payers expect? — Comparator Selection
The comparator used in the evidence submission was a composite of current treatments for advanced systemic mastocytosis, which reflects the individualized nature of treatment in clinical practice. The committee agreed that this composite comparator is a reasonable representation of the treatments currently used, despite the absence of a single licensed treatment for this condition.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trials included patients with the three subtypes of advanced systemic mastocytosis, which are clinically distinct. The committee found the trial populations to be sufficiently generalizable to Healthcare practice in England, and the inclusion of diverse subtypes enhances the relevance of the findings to the intended patient population.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Midostaurin can be integrated into existing healthcare pathways with minor adjustments. The committee noted that while some changes may be necessary, they are manageable and do not require significant new infrastructure or training, facilitating the adoption of the treatment.
Are the wider system costs understood? — Resource Use and Cost Implications
The budget impact of midostaurin is manageable, and the treatment is expected to provide significant benefits relative to its costs. The committee concluded that the resource implications are justifiable given the potential improvements in patient outcomes and quality of life.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base primarily consists of two single-arm trials, which limits the robustness of the findings. While the trials are generalizable to the Healthcare context, the lack of randomized controlled trials introduces uncertainty and potential bias. The committee acknowledged these limitations but accepted the evidence as the best available given the rarity of the condition.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are significant uncertainties regarding the clinical effectiveness and long-term outcomes of midostaurin, particularly due to the reliance on non-randomized data. The committee recognized these uncertainties but noted that the treatment addresses a significant unmet need, which may mitigate some concerns about its broader impacts.
